Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase isozyme L5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y5K5

UPID:

UCHL5_HUMAN

Alternative names:

Ubiquitin C-terminal hydrolase UCH37; Ubiquitin thioesterase L5

Alternative UPACC:

Q9Y5K5; Q5LJA6; Q5LJA7; Q8TBS4; Q96BJ9; Q9H1W5; Q9P0I3; Q9UQN2

Background:

Ubiquitin carboxyl-terminal hydrolase isozyme L5, also known as Ubiquitin C-terminal hydrolase UCH37 and Ubiquitin thioesterase L5, plays a crucial role in protein degradation. It specifically cleaves 'Lys-48'-linked polyubiquitin chains and is associated with the 19S regulatory subunit of the 26S proteasome. Additionally, it is a putative regulatory component of the INO80 complex but is activated by a transient interaction with the proteasome via ADRM1.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase isozyme L5 could open doors to potential therapeutic strategies.